Regeneron Pharmaceuticals, Inc.

Sanofi Biotechnology

Meagan P O'Brien

Jennifer D Hamilton

Gary Herman

Jamie M Orengo

Allen Radin

Sumathi Sivapalasingam

Lorah Perlee

Amanda Atanasio

Eduardo Forleo Neto

Marcella Ruddy

Heribert Staudinger

Samit Ganguly

Andrea Hooper

Flonza Isa

Kenneth Turner

The present invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods of the invention feature the administration of one or more antigen-binding molecules (e.g., antibodies) that bind a surface protein of SARS-CoV-2 (e.g., spike protein).

Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

The present disclosure provides methods for treating, preventing, or ameliorating one or more symptoms of birch allergy or allergic disease in a subject by administering to the subject an antibody or antigen-binding fragment thereof that binds Bet v 1, or a cocktail of antibodies or antigen-binding fragments thereof that bind Bet v 1.

Methods of treating allergy using anti-Bet v 1 antibodies

Methods for enhancing the efficacy, safety, and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

Growing community of inventors

New York, NY, United States of America

Meagan P O'Brien